NYSE:PKI - PerkinElmer Stock Price, Forecast & News

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

PerkinElmer announced a quarterly dividend on Thursday, January 23rd. Stockholders of record on Friday, April 17th will be paid a dividend of $0.07 per share on Friday, May 8th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date of this dividend is Thursday, April 16th. View PerkinElmer's Dividend History.

PerkinElmer, Inc. (NYSE:PKI) released its quarterly earnings data on Monday, January, 27th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.32 by $0.03. The medical research company earned $805.50 million during the quarter, compared to analyst estimates of $801.14 million. PerkinElmer had a return on equity of 16.80% and a net margin of 7.89%. The business's revenue for the quarter was up 6.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 EPS. View PerkinElmer's Earnings History.

PerkinElmer is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for PerkinElmer.

PerkinElmer updated its FY20 earnings guidance on Monday, January, 27th. The company provided EPS guidance of $4.50-4.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.63. The company issued revenue guidance of $3.05-3.09 billion, compared to the consensus revenue estimate of $3.08 billion.

13 brokerages have issued 1-year price targets for PerkinElmer's stock. Their forecasts range from $41.00 to $115.00. On average, they expect PerkinElmer's share price to reach $85.08 in the next twelve months. This suggests a possible upside of 0.9% from the stock's current price. View Analyst Price Targets for PerkinElmer.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

News coverage about PKI stock has trended extremely negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. PerkinElmer earned a news sentiment score of -4.2 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for PerkinElmer.

PerkinElmer saw a decrease in short interest during the month of February. As of February 14th, there was short interest totalling 4,950,000 shares, a decrease of 13.3% from the January 30th total of 5,710,000 shares. Based on an average daily volume of 567,600 shares, the short-interest ratio is currently 8.7 days. Approximately 4.5% of the shares of the company are sold short. View PerkinElmer's Current Options Chain.

Some companies that are related to PerkinElmer include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include NVIDIA (NVDA), AbbVie (ABBV), IBM (IBM), Visa (V), Alibaba Group (BABA), Thermo Fisher Scientific (TMO), Adobe (ADBE), Cisco Systems (CSCO), salesforce.com (CRM) and Home Depot (HD).

PerkinElmer's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (10.67%), Janus Henderson Group PLC (5.88%), Massachusetts Financial Services Co. MA (4.46%), State Street Corp (3.99%), King Luther Capital Management Corp (2.27%) and Pictet Asset Management Ltd. (2.27%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View Institutional Ownership Trends for PerkinElmer.

PKI stock was sold by a variety of institutional investors in the last quarter, including Echo Street Capital Management LLC, First Trust Advisors LP, Williams Jones Wealth Management LLC., FMR LLC, Lord Abbett & CO. LLC, Nikko Asset Management Americas Inc., Artemis Investment Management LLP and Bank of America Corp DE. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Joel S Goldberg, Pascale Witz and Prahlad R Singh. View Insider Buying and Selling for PerkinElmer.

PKI stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Massachusetts Financial Services Co. MA, KBC Group NV, Janus Henderson Group PLC, Pictet Asset Management Ltd., Alta Capital Management LLC, Cannell Peter B & Co. Inc. and State of Michigan Retirement System. View Insider Buying and Selling for PerkinElmer.

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PKI stock can currently be purchased for approximately $84.32.

PerkinElmer has a market capitalization of $9.37 billion and generates $2.88 billion in revenue each year. The medical research company earns $227.56 million in net income (profit) each year or $4.10 on an earnings per share basis. PerkinElmer employs 12,500 workers across the globe.View Additional Information About PerkinElmer.

The official website for PerkinElmer is http://www.perkinelmer.com/.

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]